Rebimastat
- Generic Name
- Rebimastat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H41N5O5S
- CAS Number
- 259188-38-0
- Unique Ingredient Identifier
- 1B47R6ZX4K
- Indication
Investigated for use/treatment in lung cancer and prostate cancer.
- Associated Conditions
- -
- Associated Therapies
- -
BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma
- First Posted Date
- 2003-08-05
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 59
- Registration Number
- NCT00024024
- Locations
- ๐บ๐ธ
Herbert Irving Comprehensive Cancer Center, New York, New York, United States
๐บ๐ธRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
๐บ๐ธWashington University School of Medicine, Saint Louis, Missouri, United States
Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2003-07-25
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 774
- Registration Number
- NCT00006229
- Locations
- ๐จ๐ฆ
CancerCare Manitoba, Winnipeg, Manitoba, Canada
๐ฆ๐นAKH Vienna, Vienna (Wien), Austria
๐บ๐ธMemorial Hospital Cancer Center - Chattanooga, Chattanooga, Tennessee, United States
Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00039104
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 68
- Registration Number
- NCT00040755
- Locations
- ๐บ๐ธ
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath